

Maraviroc

mah-RAV-er-rock

Brand Name: Selzentry

Drug Class: Entry and Fusion Inhibitors

Maraviroc, also known as Selzentry, is a type of medicine called an entry inhibitor. Entry inhibitors work by blocking HIV from entering human cells.

HIV/AIDS-Related Uses

Maraviroc received accelerated approval on August 6, 2007, and traditional approval on November 25, 2008, by the FDA for the treatment of CCR5-tropic HIV-1 in treatment-experienced adult individuals, combined with other antiretroviral treatment. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.

In 2006, Pfizer opened a worldwide expanded access program to provide maraviroc to individuals with HIV who have limited or no treatment options. The EAP will continue to provide maraviroc to individuals in countries where maraviroc is not yet available. Individuals and health care professionals can visit <http://www.maraviroceap.com> for more information.

Dosage Form/Administration

Maraviroc comes in tablet form and is taken by mouth. Maraviroc may be taken with or without food. Maraviroc is available in 150-mg and 300-mg tablets and should be given 300 mg twice daily in most individuals. Some individuals, such as those taking drugs that affect levels of maraviroc or those with kidney failure, require different doses of maraviroc.

Contraindications

Individuals should tell a doctor about any medical problems before taking this medicine.

Possible Side Effects

Along with its desired effects, maraviroc may cause some unwanted effects. The most common side effects seen in studies so far include cough, fever, dizziness, headache, lowered blood pressure, nausea, and bladder irritation. Two Phase III studies reported possible liver problems and cardiac events, an increased risk for some infections, and a slight increase in cholesterol levels.

Drug and Food Interactions

Drug interaction studies show changes in maraviroc exposure when given with other anti-HIV medications, including efavirenz and lopinavir/ritonavir. These changes require different doses of maraviroc to be used.

A doctor should be notified of any other medications being taken, including prescription, nonprescription (over-the-counter), or herbal medications.

Clinical Trials

For information on clinical trials that involve Maraviroc, visit the [ClinicalTrials.gov](http://www.clinicaltrials.gov) web site at <http://www.clinicaltrials.gov>. In the Search box, enter: Maraviroc AND HIV Infections.

Manufacturer Information

Maraviroc
Pfizer Inc
235 East 42nd Street
New York, NY 10017-5755
(800) 438-1985

Selzentry
Pfizer Inc
235 East 42nd Street
New York, NY 10017-5755
(800) 438-1985

For More Information

Contact your doctor or an AIDSinfo Health Information Specialist:

- Via Phone: 1-800-448-0440 Monday - Friday, 12:00 p.m. (Noon) - 5:00 p.m. ET
- Via Live Help: http://aidsinfo.nih.gov/live_help Monday - Friday, 12:00 p.m. (Noon) - 4:00 p.m. ET